Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 86 | SFEBES2022 | Next issue

Society for Endocrinology BES 2022

Harrogate, United Kingdom
14 Nov 2022 - 16 Nov 2022

Card image cap
SfE BES is returning to Harrogate in 2022. Join with endocrine specialists from across the UK and beyond for the Society for Endocrinology's flagship meeting.

Oral Poster Presentations

Endocrine Cancer and Late Effects

ea0086op6.1 | Endocrine Cancer and Late Effects | SFEBES2022

Post-Transcriptional regulation of wild-type and variant androgen receptors during prostate cancer progression

Lorentzen Marc , Powell Sue , Bevan Charlotte , Fletcher Claire

A key mechanism of persistent cell survival under testosterone suppression in advanced prostate cancer (PC) is continued Androgen Receptor (AR) activation. This results from AR mutation, overexpression, hyper-activation, and/or expression of constitutively-active AR transcript variants (AR-Vs). AR has an unusually long 3’ untranslated region (3’UTR), which performs vital regulatory roles but is remarkably understudied. Its contribution to continued AR activation unde...

ea0086op6.2 | Endocrine Cancer and Late Effects | SFEBES2022

Investigating the utility of microRNA signatures as a tumour biomarker in patients with succinate dehydrogenase deficient phaeochromocytoma, paraganglioma and GIST

Enright Anton , Rodgers Faye , Karcanias Alexandra , Giger Olivier , ten Hoopen Rogier , Challis Ben , Bulusu Venkata , Maher Eamonn , Casey Ruth

Background: International consensus supports interval biochemical and imaging surveillance for all asymptomatic carriers of succinate dehydrogenase (SDHx) gene mutations and patients with a history of SDH deficient tumours. There is growing awareness that the life time penetrance of the SDHx genes is much lower than that originally estimated and that long term radiological surveillance carries a significant risk including ionizing radiation exposure and incidental findings. Th...

ea0086op6.3 | Endocrine Cancer and Late Effects | SFEBES2022

Knockout mouse embryonic fibroblasts reveal a physiological role for the proto-oncogene PBF in cell adhesion and motility

Kocbiyik Merve , Manivannan Selvambigai , Brookes Katie , Zha Ling , Nieto Hannah R , Read Martin L , McCabe Christopher J , Smith Vicki E

The proto-oncogene pituitary tumor-transforming gene-binding factor (PBF) is upregulated in multiple tumours including thyroid cancer. PBF overexpression mediates tumorigenic processes such as cell motility and accelerates thyroid cancer cell invasion. We have recently shown that both PBF phosphorylation at tyrosine 174 (Y174) and PBF endocytosis are required for PBF-stimulated thyroid and breast cancer cell migration and invasion. This prompted further investigation into a ph...

ea0086op6.4 | Endocrine Cancer and Late Effects | SFEBES2022

Endocrinopathies in cancer patients receiving immune checkpoint inhibitors are associated with an improved overall survival

Murthy Sruthi , Mahmoud Sarah , Gonzalez Michael A , Martin Niamh M

Background: Immune checkpoint inhibitors (ICIs) including programmed-death cell-1 (PD-1), programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) re-activate T lymphocytes and promote cancer cell death. Immune-related adverse events (irAEs) are common in cancer patients receiving ICIs. Endocrine irAEs include primary thyroid dysfunction, hypophysitis, type 1 diabetes mellitus (T1DM) and primary adrenal insufficiency. These endocrinopathies may require a...